Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options

Bipolar Disorders

Volumn 5, Issue 2, 2003, Pages 85-97

  Yatham, Lakshmi N ^a   Calabrese, Joseph R ^b   Kusumakar, Vivek ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antidepressants; Atypical antipsychotics; Bipolar depression; Lamotrigine; Lithium; Manic swith; Refractoriness; Treatment selection; Valproate

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

BIPOLAR DEPRESSION; BIPOLAR MANIA; CLINICAL TRIAL; DATA BASE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MOOD DISORDER; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037943892     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2003.00019.x     Document Type: Review

References (60)

1. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group [published erratum appears in JAMA 1994 June 15; 271 (23): 1830] [see comments]. JAMA 1994; 271: 918-924.
2. Goodwin FK, Jamison KR. Manic Depressive Illness. Oxford: Oxford University Press, 1990.
3. Sachs GS, Altshuler L, Ketter TA et al. Divalproex versus placebo for the treatment of bipolar depression. Presented at the ACNP, Puerto Rico, December 2001.
4. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322.
5. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982; 170: 628-634.
6. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-425.
7. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants [see comments]. Br J Psychiatry 1994; 164: 549-550.
8. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179-184.
9. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555-559.
10. Kukopulos A, Caliari B, Tundo A et al. Rapid cyclers, temperament, and antidepressants. Compr Psychiatry 1983; 24: 249-258.
11. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841-850.
12. Calabrese JR, Shelton MD, Bowden CL et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62 (Suppl. 14): 34-41.
13. Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry 1995; 40: 533-544.
14. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders. I. Acute endogenous depression. Am J Psychiatry 1968; 125: 487-491.
15. Worrall EP, Moody JP, Peet M et al. Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 1979; 135: 255-262.
16. Watanabe S, Ishino H, Otsuki S. Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry 1975; 32: 659-668.
17. Mendels J, Secunda SK, Dyson WL. A controlled study of the antidepressant effects of lithium carbonate. Arch Gen Psychiatry 1972; 26: 154-157.
18. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar 1 disorder. Arch Gen Psychiatry 2003; (in press).
19. Yatham LN, Bhnke K, Timotijevic I, Naukkarinnen H, Bowden C, Thavethiran I. A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. Int J Neuropsychopharmacology 2002; 5 (Suppl. 1) S58.
20. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973; 28: 337-341.
21. Prien RF, Klett CJ, Caffey EM Jr. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974; 131: 198-203.
22. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782-790.
23. Post RM, Uhde TW, Ballenger JC, Chatterji DC, Greene RF, Bunney WE Jr. Carbamazepine and its - 10,11 -epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry 1983; 40: 673-676.
24. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34.
25. Okuma T, Inanaga K, Otsuki S et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981; 73: 95-96.
26. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-494.
27. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204.
28. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-118.
29. Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28: 221-231.
30. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161.
31. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group [see comments]. Arch Gen Psychiatry 2000; 57: 481-489.
32. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in treatment of affective disorders. Nervure 1992; 5: 57-65.
33. Calabrese JR, Rapport DJ, Kimmel SE, Reece B, woyshville MJ. Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry 1993; 38 (3 Suppl. 2): S57-S61.
34. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
35. Bowden C, Calabrese JR, Asher J et al. Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double blind placebo-controlled studies. Presented at the American College of Neuropsychopharmacology, 39th Annual Meeting, San Juan, Puerto Rico, December 2000.
36. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
37. Hauck A, Bhaumik S. Hypomania induced by gabapentin. Br J Psychiatry 1995; 167: 549.
38. Leweke FM, Bauer J, Elger CE. Manic episode due to gabapentin treatment. Br J Psychiatry 1999; 175: 291.
39. Baumhackl U, Biziere K, Fischbach R et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br J Psychiatry Suppl 1989; 6: 78-83.
40. Kessell A, Holt NF. A controlled study of a tetracyclic antidepressant - maprotiline (Ludiomil). Med J Aust 1975; 1: 773-776.
41. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
42. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatrica Scand 2001; 104: 104-109.
43. Prien RF, Kupfer DJ, Mansky PA et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-1104.
44. Tohen M, Vieta E, Ketter T et al. Olanzapine in the treatment of bipolar depression. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1):S109.
45. Tohen M, Baker RW, Altshuler L et al. Olanzapine versus divalproex sodium for bipolar mania: a 47-week study. Schizophrenia Res 2002; 53 (Suppl. 1): 183.
46. Tohen MF, Marneros A, Bowden CL et al. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month trial. Bipolar Disord 2002; 4: 135.
47. Nierenberg AA, Amsterdam JD. Treatment resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51 (Suppl. 6): 39-47.
48. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
49. Nemeroff CB, Evans DL, Gyulai L et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912.
50. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145-148.
51. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46: 794-800.
52. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124-126.
53. Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
54. Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3: 259-265.
55. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207-213.
56. Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508-512.
57. Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 2002; 63: 10-14.
58. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
59. American Psychiatric Association. Practice guidelines for treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159: 1-50.
60. Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000; 250: 57-68.